Amnion Foundation Seed Grant Program

Amnion Foundation Seed Grant Program is sponsored by Amnion Foundation. Supports advancements in regenerative medicine and drug discovery by providing primary human cells and supporting reagents derived from repurposed birth tissues. Technical support is also offered to recipients for their selected cell type(s).

Amnion Foundation Seed Grant Program amnion foundation seed grant program Recipients of Primary Cell Access Seed Grants will be eligible to receive primary cells and supporting reagents valued at up to $10,000. 00 to support an Investigator’s ongoing efforts toward the development of in vitro models or regenerative medicine products.

Amnion Foundation » Seed Grant ELIGIBILITY & APPLICATION Selected applicants will have an established, active program of applied research in placental or umbilical cord cell biology within one or more of the following disciplines: toxicology, pathogenesis, pharmacology, developmental biology, or regenerative medicine.

Applicants must have a lab in which they conduct mammalian cell culture routinely and an interest in transitioning from non-human or cancer-derived cell lines to primary human cell strains. Applicants must be an employee of a North American registered academic institution or business. Graduate students or postdoctoral trainees may apply in conjunction with the support of their primary mentor.

The application window for the 2026 Seed Grant Program is now accepting applications. If you have questions, please email info@amnionfoundation. org.

The Amnion Foundation is a registered 501(c)3 organization specializing in the repurposing of otherwise discarded birth tissues (placenta and umbilical cord) for the generation of primary human cells to support advancements in regenerative medicine and drug discovery.

Available cell types include umbilical vein-derived endothelial cells, placental tissue-derived endothelial cells, cytotrophoblasts, macrophages, classical umbilical cord-derived MSC, and pericyte-like placental stem/stromal cells. Recipients of Primary Cell Access Seed Grants will be eligible to receive primary cells and supporting reagents valued at up to $10,000.

00 to support an Investigator's ongoing efforts toward the development of in vitro models or regenerative medicine products. Technical support will also be provided to the recipients for their selected cell type(s).

Eligibility: Selected applicants will have an established, active program of applied research in placental or umbilical cord cell biology within one or more of the following disciplines: toxicology, pathogenesis, pharmacology, developmental biology, or regenerative medicine.

Applicants must have a lab in which they conduct mammalian cell culture routinely and an interest in transitioning from non-human or cancer-derived cell lines to primary human cell strains. Applicants must be an employee of a North American registered academic institution or business. Graduate students or postdoctoral trainees may apply in conjunction with the support of their primary mentor.

This field is hidden when viewing the form Next Steps: Sync an Email Add-On To get the most out of your form, we suggest that you sync this form with an email add-on. To learn more about your email add-on options, visit the following page (https://www. gravityforms.

com/the-8-best-email-plugins-for-wordpress-in-2020/). Important: Delete this tip before you publish the form. We would love to chat with you.

How can we get in touch? Your Email Address (Required) If Student / Trainee, Principal Investigator: Impact Statement (Required) Please include a statement that articulates the overall impact of completing the proposed project in the context of your field (i.e., toxicology, drug development, regenerative medicine).

Proposal (Required) Lay Abstract: Please provide a 500 word description of the project that the requested cells will support.

Project Description (Required) Please attach a 1-page description of the studies that will includes the following sections: 1) Cell type(s) requested 2) Technical description of the planned studies 3) Timeline for completion Attach the Principal Investigator's CV Here (Required) Attach the Principal Investigator's CV Here Accepted file types: pdf, png, jpg, Max. file size: 2 GB.

Applicant Signature (Required) Applicant Electronic Signature Required This field is hidden when viewing the form Seed Grant 2024 Recipients Meet our 2024 Seed Grant recipients! Each of these leading laboratories will receive no-cost access to the... Seed Grant 2025 Recipients Meet our 2025 Seed Grant recipients!

Each of these leading laboratories will receive no-cost access to the... Seed Grant 2021 Recipients Meet our 2021 Seed Grant recipients! Each of these leading laboratories will receive no-cost access to the...

“Drug use and viral infections are threats to the health of pregnant women and their unborn children. Long-term use or abuse of opioids can cause birth abnormalities, psychological disabilities, and neonatal abstinence syndrome, and Zika virus infection has caused fetal malformations, particularly abnormalities in central nervous system development.

As a result, the scientific community has turned its attention to the roles of the placental barrier and has explored the development of in vitro placental barrier models recapitulating human placental barrier physiology and pathology.

The Seed Grant from Amnion Foundation has enabled us to initiate the development of 3D human vascularized placental barrier models providing patient-derived relevant cellular components: placental microvascular endothelial cells, placental fibroblasts, and trophoblasts. The 3D placental model will allow for the study of multicellular interactions within the dynamic microenvironment during drug treatment and viral infections.

Furthermore, the high-throughput platform will provide extensive opportunities to identify better targets and drug compounds, ultimately helping researchers better predict the usefulness of therapies in patients.

” “ With relevance to pressing public health issues, toxic metals such as Arsenic and Cadmium ubiquitous in the environment, and threaten the safety and health of vulnerable populations such as pregnancy women and developing children.

These toxicants are harmful to many facets of human health, but notably are able to serve as developmental toxicants: during pregnancy they can cross the placenta and influence both the health of mother and the fetus. Toxicant exposure during pregnancy could result in immediate detrimental birth outcomes or later-in-life adverse health outcomes in children.

It is of great public health concern that research is conducted in placental cells to further our understanding of the mechanisms of action of these toxicants. The Seed Grant from Amnion Foundation has granted us the opportunity to leverage the use of primary trophoblasts to understand the association between toxic metals exposure and placental proteomic changes.

This research approach is aimed at public health improvement and is innovative in the fields of toxicology and maternal and fetal health research. ” Anastasia Freedman & Dr. Rebecca Fry, UNC-CH INTERESTED IN LEARNING MORE ABOUT THE SEED GRANT PROGRAM? Email us at info@amnionfoundation.

org or use the Get in Touch page with your questions or concerns. We’re looking forward to hearing from you!